EU-OPENSCREEN-DRIVE offers 23 fully funded research projects in the areas of chemoproteomics, small molecule screening and medicinal chemistry. Eligible proposals will be evaluated by external reviewers, and successful applicants will be selected in an open and transparent process. Transnational access comprises a total of 6 chemoproteomics, 12 small molecule screening and 5 medicinal chemistry projects.
The first call in chemoproteomics aims at increasing the understanding of mechanisms of action by which a tool or drug discovery lead compound exerts its pharmacological effect. The users are offered access to target-based and phenotype-based workflows, proteomics and related advanced mass spectrometry (MS) based technologies. EU-OPENSCREEN-DRIVE chemistry partner sites, together with partners with proven track-records in probe development, target deconvolution and MS imaging, will support 3 successful applicants, providing collaboration on target identification and compound disposition studies. Under this call, users will have the opportunity to access a broad range of experimental approaches through different chemical proteomic workflows for samples of bacterial and mammalian origin or in whole organisms (e.g. multicellular parasites).
Successful applicants get funded transnational access user projects in the field of chemoproteomics and small molecule screening at EU-OPENSCREEN-DRIVE partner sites (including personnel costs for partner site staff, partially consumables and travel costs).
For more information about the consortium and project calls: vist EU-OPENSCREEN-DRIVE homepage.
This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893